uniQure Appoints New Chief Medical Officer
Ticker: QURE · Form: 8-K · Filed: Apr 16, 2025 · CIK: 1590560
| Field | Detail |
|---|---|
| Company | Uniqure N.V. (QURE) |
| Form Type | 8-K |
| Filed Date | Apr 16, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-appointment, personnel
TL;DR
uniQure names new CMO, Dr. Hellebostad from Alnylam, effective April 16.
AI Summary
On April 15, 2025, uniQure N.V. announced the appointment of Dr. Olav Hellebostad as Chief Medical Officer, effective April 16, 2025. Dr. Hellebostad will oversee the company's global clinical development and regulatory affairs. He previously served as Chief Medical Officer at Alnylam Pharmaceuticals.
Why It Matters
The appointment of a new Chief Medical Officer is crucial for guiding the company's clinical trial strategies and regulatory submissions for its gene therapy pipeline.
Risk Assessment
Risk Level: low — This filing reports on a routine executive appointment, not a significant financial event or strategic shift.
Key Players & Entities
- uniQure N.V. (company) — Registrant
- Dr. Olav Hellebostad (person) — Appointed Chief Medical Officer
- April 16, 2025 (date) — Effective date of appointment
- Alnylam Pharmaceuticals (company) — Previous employer of Dr. Hellebostad
FAQ
Who has been appointed as the new Chief Medical Officer of uniQure N.V.?
Dr. Olav Hellebostad has been appointed as the new Chief Medical Officer of uniQure N.V.
When is the appointment of Dr. Olav Hellebostad effective?
The appointment is effective April 16, 2025.
What will be Dr. Hellebostad's primary responsibilities?
Dr. Hellebostad will oversee the company's global clinical development and regulatory affairs.
Where did Dr. Hellebostad previously work?
Dr. Hellebostad previously served as Chief Medical Officer at Alnylam Pharmaceuticals.
What is uniQure N.V.'s principal executive office address?
uniQure N.V.'s principal executive office is located at Paasheuvelweg 25a, 1105 BP Amsterdam, The Netherlands.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 16, 2025 by Dr. Olav Hellebostad regarding uniQure N.V. (QURE).